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Planning for a future inﬂ  uenza pandemic should include 
considerations speciﬁ  c to pregnant women. First, pregnant 
women are at increased risk for inﬂ  uenza-associated illness 
and death. The effects on the fetus of maternal inﬂ  uenza 
infection, associated fever, and agents used for prophy-
laxis and treatment should be taken into account. Pregnant 
women might be reluctant to comply with public health rec-
ommendations during a pandemic because of concerns 
regarding effects of vaccines or medications on the fetus. 
Guidelines regarding nonpharmaceutical interventions 
(e.g., voluntary quarantine) also might present special chal-
lenges because of conﬂ  icting recommendations about rou-
tine prenatal care and delivery. Finally, healthcare facilities 
need to develop plans to minimize exposure of pregnant 
women to ill persons, while ensuring that women receive 
necessary care. 
I
nﬂ  uenza pandemics occur when a new inﬂ  uenza type A 
virus to which the population has no immunity emerges, 
spreads efﬁ  ciently between humans, and results in world-
wide outbreaks of severe disease. Pandemics occur infre-
quently but can be devastating in terms of the effects on 
illness and mortality. Most inﬂ  uenza experts consider in-
ﬂ  uenza pandemics inevitable (1). The emergence of avian 
inﬂ  uenza A virus (H5N1) as a cause of severe human infec-
tions has increased concerns about an impending pandem-
ic. Although human disease caused by inﬂ  uenza (H5N1) 
is a rare event (2), the virus has become endemic among 
bird populations in some areas of Asia and has continued to 
spread geographically and to broaden its host range. Con-
cerns that the virus might acquire the ability to efﬁ  ciently 
spread between humans have led public health authorities 
to accelerate preparations for pandemic inﬂ  uenza.
A key component of pandemic preparedness (3) in-
volves addressing the speciﬁ  c needs of vulnerable popu-
lations, including pregnant women. Pregnant women are 
at high risk for severe complications of inﬂ  uenza during 
interpandemic periods (4) and previous pandemics (5–8). 
In addition, some studies suggest an increased risk for ad-
verse outcomes among infants born to mothers infected 
with inﬂ  uenza during pregnancy (9–12). Special consid-
erations for pregnant women should be addressed in all 
3 categories of public health response to pandemic inﬂ  u-
enza—nonpharmaceutical interventions, antiviral medica-
tions, and vaccines. Many articles have discussed issues 
regarding pandemic inﬂ  uenza in the general population, 
but limited attention has been given to the effects on the 
pregnant woman and her fetus. This article focuses on is-
sues regarding pregnant women that should be considered 
by public health and medical professionals as they prepare 
for a future inﬂ  uenza pandemic.
Pandemic versus Seasonal Inﬂ  uenza
Inﬂ  uenza viruses that infect humans are classiﬁ  ed into 
3 principal types (A, B, and C), of which types A and B are 
important causes of human disease. Types A and B are as-
sociated with seasonal epidemics; only type A viruses have 
caused pandemics. Inﬂ  uenza A viruses are further classiﬁ  ed 
on the basis of 2 surface proteins, hemagglutinin (H) and 
neuraminidase (N). Minor mutations that result in subtle 
changes in these proteins (antigenic drift) occur continu-
ously. Because these mutations produce viruses that can be 
sufﬁ  ciently different antigenically from previous inﬂ  uenza 
viruses, inﬂ  uenza vaccines must be updated annually. More 
dramatic changes in the surface proteins of inﬂ  uenza vi-
ruses, through mutation of nonhuman (e.g., avian or swine) 
viruses or reassortment of human and nonhuman viruses, 
result in the creation of novel human subtypes (termed an-
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tigenic shift). When novel subtypes that can be efﬁ  ciently 
transmitted among humans emerge within a population that 
lacks immunity, an inﬂ  uenza pandemic can occur (3).
Avian species are an important reservoir for inﬂ  uenza 
virus, but avian inﬂ  uenza viruses do not typically infect 
humans. However, in 1997, human exposure to ill birds 
infected with avian inﬂ  uenza A (H5N1) led to a severe 
outbreak in Hong Kong Special Administrative Region, 
People’s Republic of China.The H5N1 virus subtype re-
emerged in early 2003, and since that time, the virus has 
caused poultry and wild bird illnesses in >50 countries. In 
addition, 321 conﬁ  rmed human cases of inﬂ  uenza (H5N1) 
in 12 countries have been reported to the World Health Or-
ganization, 194 of which have resulted in death (2). Thus 
far, inﬂ  uenza (H5N1) transmission has been predominantly 
bird-to-human, but the ongoing avian disease and occasion-
al human disease have raised concerns about the possibility 
that this virus could gain the capacity for efﬁ  cient human-
to-human transmission and possibly lead to an inﬂ  uenza 
pandemic (3). Although inﬂ  uenza (H5N1) represents the 
greatest current threat for a pandemic virus, global public 
health authorities recommend increased vigilance for any 
novel inﬂ  uenza virus infections in humans as a cornerstone 
of pandemic preparedness.
Effects of Inﬂ  uenza on Pregnant Women
Pregnancy has been a risk factor for increased illness 
and death for both pandemic and seasonal inﬂ  uenza. The 
increased risk is believed to be related to several physio-
logic changes that occur during pregnancy. Because of me-
chanical and hormonal alterations that occur during preg-
nancy, several changes also occur to the cardiovascular and 
respiratory systems, including increased heart rate, stroke 
volume, oxygen consumption, and decreased lung capacity 
(13). Relevant immunologic alterations also occur during 
pregnancy, with a shift away from cell-mediated immunity 
toward humoral immunity. This shift can render pregnant 
women more susceptible to, or more severely affected by, 
certain viral pathogens, including inﬂ  uenza (14).
Although appropriate nonpregnant control groups 
were generally not available, mortality rates among preg-
nant women in the pandemics of 1918 and 1957 appeared 
to be abnormally high (5,7). Among 1,350 reported cases 
of inﬂ  uenza among pregnant women during the pandemic 
of 1918, the proportion of deaths was reported to be 27% 
(5). Similarly, among a small case series of 86 pregnant 
women hospitalized in Chicago for inﬂ  uenza in 1918, 45% 
died (6). Among pregnancy-associated deaths in Minnesota 
during the 1957 pandemic, inﬂ  uenza was the leading cause 
of death, accounting for nearly 20% of deaths associated 
with pregnancy during the pandemic period; half of women 
of reproductive age who died were pregnant (7).
Pregnant women have also been shown to be at in-
creased risk for inﬂ  uenza complications during interpan-
demic periods (15). In a large study of >4,300 women of re-
productive age during 19 interpandemic inﬂ  uenza seasons, 
pregnant women were compared with postpartum women 
(a group considered to be most similar to pregnant women 
demographically and with regard to their health) and were 
found to be signiﬁ  cantly more likely to be hospitalized for 
a cardiopulmonary event during the inﬂ  uenza season (4). 
The risk for hospitalization increased as pregnancy pro-
gressed, with women at term nearly 5 times more likely 
to be hospitalized than postpartum women (4). Similarly, 
during 3 inﬂ  uenza seasons in the late 1970s, rates of medi-
cal visits for acute respiratory disease were more than twice 
as high among pregnant women than nonpregnant women 
(16). At particularly high risk during the inﬂ  uenza season 
are pregnant women with underlying medical conditions 
for which inﬂ  uenza vaccination is recommended, such as 
asthma (17). On the basis of these data, pregnant women 
should be considered a population for which special con-
siderations for prevention and treatment for inﬂ  uenza need 
to be made.
Effects of Inﬂ  uenza on the Fetus
Although certain infections are well recognized to 
increase the risk for adverse pregnancy outcomes, the ef-
fects of maternal inﬂ  uenza infection on the fetus are not 
well understood. Viremia is believed to occur infrequently 
in inﬂ  uenza (18), and placental transmission of the virus 
also appears to be rare (19). However, even in the absence 
of fetal viral infection, animal studies suggest that adverse 
effects can still occur. Prenatal inﬂ  uenza infection in the 
mouse has been associated with histopathologic changes in 
the brain (20) and behavioral alterations (21) in offspring. 
Although inﬂ  uenza virus RNA has not been detected in the 
fetal brain, these changes suggest that fetal effects could 
be secondary to the maternal inﬂ  ammatory response, rather 
than the result of a direct viral effect (22).
Adverse pregnancy outcomes have been reported fol-
lowing previous inﬂ  uenza pandemics. During the inﬂ  uenza 
pandemic of 1918, remarkably high rates of spontaneous 
abortion and preterm birth were reported (5,6), especially 
among women with pneumonia (for example, in 1 study, 
>50% of pregnancies in which the pregnant woman had 
inﬂ  uenza and accompanying pneumonia were not carried 
successfully to term) (5). During the Asian inﬂ  uenza pan-
demic of 1957, studies suggested a possible increase in 
defects of the central nervous system (10–12) and several 
other adverse outcomes, including birth defects, spontane-
ous pregnancy loss, fetal death, and preterm delivery (8). 
Studies of the effects of seasonal inﬂ  uenza infection on the 
fetus have been contradictory. A small increased risk for 
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birth defects in general and for speciﬁ  c birth defects have 
been observed in some but not all studies (9). Using data 
from a recent case-control study, investigators showed that 
mothers of infants with any type of birth defect were slight-
ly more likely to report inﬂ  uenza during early pregnancy 
than mothers of control infants (adjusted odds ratio 1.4; 
95% conﬁ  dence intervals 1.3–1.6), with statistically signif-
icant associations for cleft lip with or without cleft palate, 
and neural tube and congenital heart defects. Veriﬁ  cation 
of maternal report of inﬂ  uenza illness with prospectively 
collected clinical data was possible for similar numbers of 
case and control infants (9), which suggests that recall bias 
was unlikely to explain the association. The risk associ-
ated with inﬂ  uenza was reduced for women who received 
treatment with antifever medications and for those who had 
taken folic acid before and during early pregnancy (9).
Associations between maternal inﬂ  uenza  infection 
after both pandemic and seasonal inﬂ  uenza and outcomes 
observed long after birth have been reported. Associations 
between maternal inﬂ  uenza infection and childhood leuke-
mia (23), schizophrenia (24), and Parkinson disease (25) 
have been suggested by some studies. Even if the inﬂ  uenza 
virus does not have a direct effect on the fetus, fever that 
often accompanies inﬂ  uenza infection could have adverse 
effects. Both animal and human epidemiologic studies sug-
gest that hyperthermia is associated with an increased risk 
for adverse outcomes (26), especially neural tube defects 
(27). Factors that might attenuate this risk include shorter 
fever duration (28), use of fever-reducing medications (28–
30), and use of folic acid–containing supplements (29,31).
More study is needed to better understand the fetal risks 
of maternal inﬂ  uenza infection. However, data from previ-
ous pandemics, although limited, suggest that pregnancy 
loss and preterm delivery could be important issues during 
a future inﬂ  uenza pandemic. Information on seasonal inﬂ  u-
enza indicates that inﬂ  uenza infection or its accompanying 
hyperthermia might also increase the risk for certain birth 
defects. Data on these potential risks to the fetus, combined 
with available information on risks for inﬂ  uenza infection 
on maternal health, provide ample support for consider-
ing pregnant women a high-risk population in an inﬂ  uenza 
pandemic.
Pandemic Inﬂ  uenza Response 
for Pregnant Women
Nonpharmaceutical Interventions
A main component of the public health response to 
pandemic inﬂ  uenza will be nonpharmaceutical interven-
tions to mitigate disease rates and severity and the societal 
impact of the pandemic beyond health outcomes. The Cen-
ters for Disease Control and Prevention recently released 
guidance for nonpharmaceutical interventions during a 
pandemic that focuses on isolation of ill persons, volun-
tary quarantine of households with ill persons, and social 
distancing techniques (e.g., avoiding crowded settings, 
closing schools and child care centers) to limit exposure 
to ill persons (32). However, these recommendations pres-
ent special challenges for pregnant women. For example, 
pregnant women will need guidance on how to protect 
themselves from becoming infected (e.g., use of protective 
devices) if they are quarantined with or directly providing 
care for ill persons. Responsibilities of pregnant women as 
members of the workforce and as caregivers of their chil-
dren and other family members may further complicate 
their adherence to public health recommendations. In ad-
dition, because healthy pregnant women will continue to 
require both outpatient prenatal care and inpatient delivery 
services during a pandemic, they might be more likely to 
be exposed to clinical settings where ill persons are re-
ceiving care. Given the potential risk to women in clini-
cal settings, guidance will need to be developed regarding 
whether some routine prenatal care visits could be omitted. 
Healthcare facilities need to develop plans to ensure that 
pregnant women receive necessary care, but with minimal 
exposure to ill persons or their contacts. In addition, plans 
for care and delivery of pregnant women with conﬁ  rmed 
inﬂ  uenza or recent exposure must ensure that these women 
receive appropriate care without unduly exposing other 
healthy pregnant women and their infants to illness. An 
appropriate strategy to address these issues might include 
designating a location and staff for care of pregnant women 
and their newborns, separate from those used by patients 
with inﬂ  uenza. Another strategy could include develop-
ing an algorithm that triages pregnant patients on the basis 
of pregnancy stage and symptoms to ensure that pregnant 
women most in need of attention receive care, but avoid the 
risk of inﬂ  uenza exposure when that risk might be greater 
than the beneﬁ  t of care. Consideration of these strategies 
as part of overall community pandemic planning activities 
will be essential.
Experience from the international outbreak of severe 
acute respiratory syndrome (SARS) (33) can shed light on 
how to approach these complicated issues. In Toronto, ob-
stetric services were moved into a newly designed facil-
ity that had entrances, elevators, and air-handling systems 
that were separate from the rest of the hospital. Hospital 
staff, patients, and visitors were screened at the hospital 
entrance for SARS symptoms and to ensure that they had 
not visited a SARS-affected area. Staff members wore N95 
respirator masks, face shields or eye protection, gowns, 
and non-latex gloves, and employed frequent hand wash-
ing with ethanol-based gels. Patients were limited to 1 
visitor during labor and delivery, and no visitors were al-
lowed on postpartum wards. All patients and visitors wore 
N95 respiratory masks. The length of postpartum stay was 
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decreased and, after discharge, women were instructed to 
stay at home under quarantine for 10 days; a nurse visited 
them on their third day postpartum. Healthcare workers 
were asked to observe work quarantine; they were encour-
aged to go directly to work and home minimizing contact 
with the public (34). In Hong Kong, obstetric services were 
transferred to a hospital separate from hospitals in which 
SARS cases were managed. Women were discharged 
sooner after delivery, and all obstetric services considered 
nonessential (e.g., routine ultrasonography and prenatal di-
agnosis) were temporarily suspended (33).
Antiviral Medication Use by Pregnant Women
During a pandemic, 2 pharmaceutical options—an-
tiviral medications and vaccination—will be available to 
reduce the expected illness and death. Given that a vac-
cine is unlikely to be available for a substantial portion of 
the population at the beginning of a pandemic, antiviral 
medications are expected to play an important role in the 
response to pandemic inﬂ  uenza, both for postexposure pro-
phylaxis and for inﬂ  uenza treatment. Two antiviral medica-
tions are currently recommended for treatment and prophy-
laxis of inﬂ  uenza in humans (15). These medications, both 
neuraminidase inhibitors, are available in oral (oseltamivir 
[Tamiﬂ  u]) and inhaled (zanamivir [Relenza]) forms, and 
make up the bulk of stockpiled anti-inﬂ  uenza medications. 
Two additional anti-inﬂ   uenza medications, the M2 ion 
channel blockers rimantidine and amantadine, are currently 
not recommended for use because of high rates of resis-
tance among circulating human inﬂ  uenza A viruses and 
some avian inﬂ  uenza viruses.
As is the case with >90% of medications introduced in 
recent years (35), insufﬁ  cient information on oseltamivir 
and zanamivir is available to assess potential risks to the fe-
tus. This is reﬂ  ected by their category C use-in-pregnancy 
rating from the US Food and Drug Administration (i.e., in-
sufﬁ  cient information available to assess their potential risk 
and beneﬁ  t during pregnancy) (35). Animal studies have 
shown no evidence of increased risk for adverse effects for 
either medication (36,37), but animal data do not always 
predict the effects on human pregnancies (35). Human data 
are very limited. Among 61 pregnant women exposed to 
oseltamivir in the post-marketing period, most pregnan-
cies had a normal outcome (36). Single cases of trisomy 21 
and anencephaly were reported among these exposed preg-
nancies, but these cases were not believed to be causally 
related to oseltamivir exposure. Three pregnancies were 
inadvertently exposed to zanamivir during the clinical tri-
als, with one ending in spontaneous abortion, one in elec-
tive termination, and one in an outcome with no apparent 
adverse effects (37). The bioavailability (the proportion of 
active drug that reaches the systemic circulation) of zana-
mivir is lower (12%–17%) than that of oseltamivir (≈80%) 
(38), leading some to suggest that it might be preferred dur-
ing pregnancy (3).
Many pregnant women will require treatment with oth-
er medications, such as antibiotics for secondary bacterial 
pneumonia and antipyretic medications for fever control. 
Healthcare providers need access to information on these 
medications and their safe use during pregnancy so that ef-
fects on the fetus can be taken into account.
Another issue to consider is that even in the case of 
serious exposure or illness, pregnant women might fail to 
comply with recommendations for use of antiviral medica-
tions because of concern for the health of the fetus. This 
emphasizes the importance of communication of the risks 
and beneﬁ  ts of medications and the serious nature of un-
treated inﬂ  uenza. As with all communications related to 
pandemic inﬂ  uenza, messages must be culturally and lin-
guistically appropriate and conducted at an appropriate 
level of literacy to ensure such efforts are inclusive, given 
the diversity of the population of pregnant women.
Further research to understand the effects of anti-in-
ﬂ  uenza medications on the pregnant woman and her fetus 
is essential to guide treatment recommendations during 
a future pandemic. Although exposures to these medica-
tions are likely to be rare in the pre-pandemic period, col-
lection of data on these exposures in a pregnancy registry, 
as has been used to collect data on other rare exposures 
(35), could provide important data to guide pandemic rec-
ommendations. In the absence of additional information, 
healthcare providers will need to consider the type of ex-
posure, risk for serious illness or death, and trimester of 
pregnancy when weighing the risks and beneﬁ  ts of these 
medications to the woman and her fetus. Guidelines for the 
pandemic scenario, similar to those developed for manage-
ment of sporadic avian inﬂ  uenza (H5N1) infection (39), 
could assist healthcare providers in weighing these risks 
and beneﬁ  ts.
Use of Pandemic Inﬂ  uenza Vaccine 
among Pregnant Women
Once available, a vaccine will be a vital component 
of the public health response to pandemic inﬂ  uenza. Given 
their increased risk for illness and death during pandemic 
inﬂ  uenza, pregnant women should be considered a high 
priority for receipt of inﬂ  uenza vaccine. Several studies 
have demonstrated no adverse fetal effects when women re-
ceived inactivated vaccine during pregnancy (15,40). Both 
the Advisory Committee on Immunization Practices and 
the American College of Obstetricians and Gynecologists 
recommend annual vaccination with trivalent inactivated 
inﬂ  uenza vaccine for women who will be pregnant during 
the inﬂ  uenza season (October–mid May) to prevent sea-
sonal inﬂ  uenza (15,40). (Live, attenuated, inﬂ  uenza virus 
vaccine, available as an intranasal spray, is not approved 
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for use during pregnancy, given the theoretical risk associ-
ated with use of live vaccine during pregnancy.) Inactivat-
ed inﬂ  uenza vaccine is recommended in all 3 trimesters of 
pregnancy (15,40). Despite these recommendations, com-
pliance has been low (15), probably because of concerns 
among women and their healthcare providers regarding 
the safety of vaccination during pregnancy. Development 
of culturally and linguistically appropriate messages will 
be necessary to ensure that pregnant women receive infor-
mation regarding care required for their health and that of 
their fetus in the event of a future pandemic. Professionals 
who develop these messages need to be aware that some 
women will have limited access to healthcare services. In-
novative strategies will be needed to ensure that these mes-
sages reach them.
Incorporating Issues of Pregnant 
Women into Preparedness Exercises
Pandemic inﬂ  uenza planning that speciﬁ  cally address-
es the concerns of pregnant women is critical because spe-
cial issues need to be considered for this high-risk group. 
Pandemic inﬂ  uenza preparedness exercises should include 
scenarios in which issues speciﬁ  c to pregnant women re-
quire attention. In the event of an inﬂ  uenza pandemic, iden-
tiﬁ  cation and close monitoring of pregnant women will be 
important, given their increased risk for inﬂ  uenza-associ-
ated illness and death. Intake procedures for women seek-
ing prophylaxis and treatment for pandemic inﬂ  uenza need 
to incorporate questions about the possibility of pregnancy. 
By including scenarios involving pregnant women in pan-
demic inﬂ  uenza preparedness exercises, public health pro-
fessionals will have the opportunity to weigh the risks and 
beneﬁ  ts of anti-inﬂ  uenza medications in the context of a 
speciﬁ  c pandemic scenario. Their inclusion in preparedness 
exercises will help to identify gaps in our current capacity 
to provide optimal care for this high-risk population.
Conclusions
Because of their risk for severe disease and death and 
the potential for risk for the fetus, pregnant women should 
be considered to be high-risk in the event of an inﬂ  uenza 
pandemic. Research into the effects of maternal inﬂ  uenza 
and its treatment on the pregnant woman and her fetus is 
sorely needed. Based on the limited information available, 
pregnant women who become ill with inﬂ  uenza should be 
treated aggressively with antifever therapy, and should ad-
here to standard recommendations for folic acid consump-
tion (9). Given the limited data currently available, plans 
for prophylaxis and treatment for pandemic inﬂ  uenza will 
need to include reassessment of risks of inﬂ  uenza and risks 
and beneﬁ  ts of treatment strategies as a pandemic evolves. 
In addition to incorporating considerations speciﬁ  c to preg-
nant women into pandemic inﬂ  uenza planning efforts, strat-
egies to communicate this guidance to pregnant women and 
their healthcare providers must be planned, developed, and 
tested. Only through consideration of all these issues, from 
research and planning to communications and intervention, 
will the health and well-being of pregnant women be en-
sured in a future inﬂ  uenza pandemic.
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